Presentation on theme: "Parkinson Disease (PD) Treatment Update. Outlines The Basics: – PD Introduction and motor symptoms. – DDx not to miss. – Different classes of Anti PD."— Presentation transcript:
Outlines The Basics: – PD Introduction and motor symptoms. – DDx not to miss. – Different classes of Anti PD. Dopamine. Dopamine Agonist. MAO inhibitors. COMT inhibitors. Anticholinergics Amantadine – Non motor symptoms and Rx. – Role of Surgery.
Objectives – Describe the characteristics of different classes of drugs used in Parkinson disease treatment. – Treatment of non-motor symptoms – Role of Surgery in PD Rx.
PD Introduction and Cardinal features Described 1st by James Parkinson 1817 Average incidence 200 in 100000. Multifactorial, dopaminergic neuronal loss SNc. Cardinal Motor features: – Resting tremor: absent in 20% of patient. – Bradykinesia – Rigidity – Impairment of postural reflex. Diagnosis is clinical.
Think of other Diagnosis if : – Early falls – Poor response to levodopa – Symmetry at onset – Rapid progression – Lack of tremor – Prominent dysautonomia. Predictors of benign course: Young onset, Resting tremor. Poor outcome: elder, male, hypokinesia…
Levodopa Naturally occuring amino acid (3,4-dihydroxy-l- phenylalanine), intermediate in dopamine synthesis. Absorbed actively by neutral amine transporter. Crosses blood brain barrier. Carbidopa dose not. Metabolism: Decarboxylation and O-methylation Half life: 1.5 hour with carbidopa. Time to peak: 0.5 hours; Controlled release: 2 hours. Excretion: Urine ( metabolites).
Levodopa Uses: – PD any stage. – Help all motor symptoms, but not retropulsive imbalance. Some times dose not help tremor. Dose: – Initial: 150 mg of levodopa and 75 mg of carbidopa/benserazide divided in 3 doses. – Max 2000 mg /200mg levo/carbodopa. – Sustained release form available 100 to 200 mg tablets. Side effects: – Nausea / hypotention. Reduced by carbidopa. – Chronic: motor fluctuation, dyskinesia. As early as 2 years. By 5 years 50% have it. Correlate with high dose and younger age. – Abrupt stop may cause a syndrome similar to malignant nueroleptic S.
levodopa Motor fluctuation: – Off phenomena: Occurs before next dose ( return of bradykinesia/tremor). some patients may experience dysphoria, anxiety, or sensory phenomena. Other non-motor symptoms. Painful leg cramps early AM ( off dystonia). – Dyskinesia: Choreoathetoid movement any part (legs/cervical). Stress induced initially. At peak-dose of LD.
Dopamine Agonist Pramipexole: – Uses: early PD, Late PD with motor fluctuation…RLS – More specific to D3 receptor. Less hypotension. – Improve motor activity within 2-3 wks. – Kinetics: 15% protien bound, active excretion kidney( 90%) unchanged drug. – Dose: ( start low go slow) 0.25 mg TID, max 1.5TID – Reduction of L-Dopa requirment by 25%.
Dopamine Agonist Ropinirol: – Uses: – Act on both D2,3 centrally. D2 peripherally ( SE conteracted by Domperidone). – Metabolised by cytochrome P-450, inactive metabolites…urine 90%. – Doses: initial 0.25 mg TID weekly increment. Max dose 24mg/day. – Discontinuation: gradual over one week.
Dopamine Agonist Bromocriptine: – Uses: early and advanced PD, hyperprolactin. – Reduce L-Dopa requirement by 40%. – 90% protein bound, biliary excretion. – Dose 1.25mg BID increase by 2.5mg 1-2 wks. Max100mg.
Dopamine Agonist Apomorphine: – SC DA. Onset 7-15 min. duration 2 hours. – Useful as rescue for off times. – Emesis within 3-10 min. hypotension. – Extensive hepatic metabolism. – Initials doses 1mg SC TID. Max 20mg/day.
catechol-O-methyltransferase (COMT) inhibitors Tolcapone:(Inhibit central COMT, Fatal hepatoixcty ). Entacapone: (peripheral COMT inhibition). – Increase on time by 1-1.7 hour. – reduction in l-dopa dose. – Safe with other DA. – Dose : 200 mg with each L-dopa (combined tablet Stalevo). – SE: increase Dyskinesia ( decrease 20-30% L-dopa) – N/V, abd pain, urine discoloration, diarrhea.
De Novo PD AAN recommendation Either L-Dopa ( better for motor disability) or dopamine agonist( less motor complication) may be used for initial Rx of PD. (Level A). Either sustained release or immediate release L-dopa may be considered in initial treatment of PD. (Level B)
AAN recommednations Use Entacapone and Rasagiline to reduce off time ( Level A). Pramipexol, ropinirole, pergolide, tolcapone should be considered to reduce off time. (Level B). Apomorphine, cabergoline, selegiline may be cosidered to reduce off time. (Level C). Bromocribtine, sustained release l-dopa may be disregarded to reduce off time (level C).
Surgical Rx Steriotatic lesion to pallidothalamic pathways used before L-dopa discovery. Limited due to risk of perminant neuro damage. Deep Brain electrical stimulation: – Restricted to those who failed medical Rx. – Subthalamic N: – Globus Pallidus
AAN updated evidence DBS of STN possibly effective in improving motor function/reduce motor fluctuation/dyskinesia. Class III ( level C). Preoperative response to L-Dopa, younger age and less duration of PD predict greater imporvment after DBS of STN. ( level B) DBS of Gpi: insufficent evidence to support of refute effectivenss class III.
references Levodopa for the Treatment of Parkinson's Disease. N Engl J Med 2008; 359:2468- 2476December 4, 2008December 4, 2008 A reassessment of risks and benefits of dopamine agonists in Parkinson's disease Lancet Neurology. Entacapone in the treatment of Parkinson's disease Lancet Neurology. CONTINUUM: Lifelong Learning in Neurology June 2004; Volume 10(3); pp 15-41 Treatment of motor and non-motor features of Parkinson's disease with deep brain stimulation. Lancet neurology AAN practice Guidelines : initiation of treatmetn for parkinson disease. Treatment of PD with motor fluctuation and dyskinesia.